September 15, 2020—The Foundation for the National Institutes of Health (FNIH) and the National Institute of Mental Health (NIMH), a part of the National Institutes of Health (NIH), announce the Accelerating Medicines Partnership in Schizophrenia (AMP SCZ), the first neuropsychiatric project of the landmark Accelerating Medicines Partnership (AMP) program managed by the FNIH. This five-year, $99 million global public-private partnership pioneers the identification of the early indicators of schizophrenia to catalyze better treatments for patients.
September 15, 2020—The National Institutes of Health is launching a new public-private partnership to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia. Part of the Accelerating Medicines Partnership (AMP), AMP Schizophrenia (SCZ) brings together NIH, the U.S. Food and Drug Administration and multiple non-profit and private organizations. These partners will work toward the shared mission of discovering promising biological markers that can help identify those at risk of developing schizophrenia as early as possible, track the progression of symptoms and other outcomes and define targets for treatment development.
Last Reviewed on May 2, 2022